Patricia Culp

This inventor holds 13 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Alector LLC, Abbvie Biotherapeutics Inc.. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patricia Culp. Retrieved from https://idiyas.com/inventor/patricia-culp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 8)

% Patents Active = 92.3

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 23(Granted Patents)

Company Filing History:

Abbvie Biotherapeutics Inc.

patents

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Anti-Siglec-5

Anti-SIRPα

Anti-CD33

Anti-Siglec-7

Anti-SIRP-Beta1

Anti-SIRPa

Bispecific Binding Proteins

CD40

Mesothelin

Tweak Receptor Antibodies

Therapeutic Use

Immunotherapy

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258410 - Anti-SIRPα antibodies and methods of use thereof (2025-03-25),

2. 12258398 - Anti-Siglec-5 antibodies and methods of use thereof (2025-03-25),

3. 12247073 - Anti-CD33 antibodies and methods of use thereof (2025-03-11),

4. 12227568 - Anti-Siglec-7 antibodies and methods of use thereof (2025-02-18),

5. 12060422 - Anti-SIRP-Beta1 antibodies and methods of use thereof (2024-08-13),

6. 11976119 - Anti-SIRPa antibodies and methods of use thereof (2024-05-07),

7. 11965023 - Anti-Siglec-5 antibodies and methods of use thereof (2024-04-23),

8. 11359014 - Anti-siglec-5 antibodies and methods of use thereof (2022-06-14),

9. 11319373 - Anti-SIRPA antibodies and methods of use thereof (2022-05-03),

10. 11254743 - Anti-CD33 antibodies and methods of use thereof (2022-02-22),

11. 10711062 - Anti-CD33 antibodies and methods of use thereof (2020-07-14),

12. 10233258 - Bispecific binding proteins that bind CD40 and mesothelin (2019-03-19),

13. 9056908 - Therapeutic use of anti-tweak receptor antibodies (2015-06-16),

Title: The Innovative Mind of Patricia Culp

Introduction

Patricia Culp, an accomplished inventor based in Oakland, CA, has made significant contributions to the field of biotherapeutics. With 13 patents to her name, Culp has developed groundbreaking technologies aimed at advancing medical treatments and therapies.

Latest Patents

Among Patricia's latest patents are the "Anti-SIRPα antibodies and methods of use thereof," which disclose compositions including monoclonal antibodies that specifically bind to SIRPA polypeptides. This innovation holds potential for preventing or treating individuals in need. Another significant patent is the "Anti-Siglec-5 antibodies and methods of use thereof," focusing on monoclonal and humanized antibodies that bind to Siglec-5 proteins, offering similar therapeutic applications.

Career Highlights

Patricia has worked with renowned companies like Alector LLC and AbbVie Biotherapeutics Inc., where she applied her expertise in antibody development. Her career is marked by a commitment to advancing the field of immunotherapy and addressing urgent health challenges through innovative solutions.

Collaborations

Over the years, Patricia has collaborated with notable professionals in her field, including Arnon Rosenthal and Helen Lam. These partnerships have fostered a collaborative spirit that often leads to innovative breakthroughs in medical research and product development.

Conclusion

Patricia Culp exemplifies the spirit of innovation in the biomedical field. Her dedication to her work and the development of patents that address significant medical needs showcases her status as a leading inventor. As the landscape of biotherapeutics continues to evolve, Patricia's contributions will undoubtedly play a crucial role in shaping the future of healthcare.

Profile summary based on public USPTO records.